William Blair Has Optimistic Outlook of LRMR Q2 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMRFree Report) – Investment analysts at William Blair lifted their Q2 2025 earnings per share estimates for Larimar Therapeutics in a research note issued on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will earn ($0.50) per share for the quarter, up from their prior estimate of ($0.51). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and FY2026 earnings at ($2.05) EPS.

Larimar Therapeutics (NASDAQ:LRMRGet Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Other analysts also recently issued reports about the stock. Guggenheim reissued a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. HC Wainwright boosted their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 25th. Robert W. Baird lowered their price target on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Truist Financial assumed coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $19.63.

View Our Latest Report on LRMR

Larimar Therapeutics Stock Down 9.4 %

LRMR stock opened at $2.69 on Monday. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $11.20. The firm has a market cap of $172.24 million, a PE ratio of -2.34 and a beta of 0.93. The business has a 50 day moving average of $2.36 and a 200 day moving average of $4.17.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its holdings in shares of Larimar Therapeutics by 15.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after purchasing an additional 876,431 shares during the last quarter. Blue Owl Capital Holdings LP increased its stake in Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after acquiring an additional 486,211 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Larimar Therapeutics by 23.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after acquiring an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after acquiring an additional 273,920 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Larimar Therapeutics by 45.1% in the fourth quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock valued at $1,987,000 after purchasing an additional 159,700 shares in the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Further Reading

Earnings History and Estimates for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.